Condition category
Circulatory System
Date applied
18/05/2016
Date assigned
22/06/2016
Last edited
29/06/2016
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
A stroke is a serious condition where the blood supply to a part of the brain is cut off, usually by a blood clot blocking an artery (ischaemic stroke) or a bleed (haemorrhagic stroke). A large proportion of stroke victims suffer from long-term complications depending on the area of the brain that is affected, which can affect their ability to move, speak or even their cognitive function (memory loss, difficulty reasoning and confusion). This requires extensive care both in the short and long term. The early stages of the stroke care pathway are becoming more prescribed (treatment in acute and rehabilitation stroke units), but despite policy recommendations, strategies for longer-term care are not developed and stroke survivors and their families face a number of problems and challenges. This is looking at a new system (Moving Forward) for longer-term stroke care which has been developed to help improve the mental and physical wellbeing of patients (and their carers) living at home following a stroke. The aim of this study is to find out whether undertaking a large-scale study investigating the effectiveness of this tool is feasible.

Who can participate?
Stroke services located in participating hospitals in the UK; stroke survivors who had a stroke 4-7 months ago who live at home and their carers.

What does the study involve?
Participating sites are randomly allocated to one of two groups. Those in the first group receive standard care as provided by their treating clinician. Those in the second group take part in the Moving Forward program, a strategy based upon analyses of the needs of stroke survivors and what helped and hindered them to address these needs. It involves taking part in an initial face-to-face meeting with a trained facilitator to identify any unmet needs and then to work to address these needs over later sessions. At the meeting, these issues and needs are discussed and a supported self-management approach is introduced with the aim of addressing needs through individualised problem-solving. The process involves facilitated action-planning, goal-setting, and review, all of which are supported by a flexible document – the Moving Forward Guide. Stroke survivors can have as many meetings with the facilitators as required, but it is thought that most need at least three visits and support may also be provided via the internet, phone or email. Participants in both groups complete a number of questionnaires at the start of the study and then after three, six and 12 months about their mental and physical wellbeing. The acceptability of the program is then measured through interviews and specially designed questionnaires, and the number of participants who complete the follow up questionnaires is recorded.

What are the possible benefits and risks of participating?
There are no known benefits or risks involved with participating in this study.

Where is the study run from?
Edgeware Community Hospital and six other NHS hospitals in England and Wales (UK)

When is the study starting and how long is it expected to run for?
February 2015 and September 2019

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Ms Lorna Barnard
l.j.barnard@leeds.ac.uk

Trial website

Contact information

Type

Public

Primary contact

Ms Lorna Barnard

ORCID ID

Contact details

Clinical Trials Research Unit
Leeds Institute of Clinical Trials Research
University of Leeds
Leeds
LS2 9JT
United Kingdom
+44 113 343 0504
l.j.barnard@leeds.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

30510

Study information

Scientific title

A longer-term care strategy to support stroke survivors and their carers (LoTS2Care) –A feasibility study

Acronym

Study hypothesis

The aim of this study is to undertake a feasibility cluster randomised controlled trial (cRCT) of a purposely developed intervention ‘Moving Forward’ to inform a future definitive cRCT to investigate the clinical and cost-effectiveness of the Moving Forward intervention for stroke survivors.

Ethics approval

Yorkshire & The Humber - Leeds East Research Ethics Committee, 26/04/2016, ref: 16/YH/0068

Study design

Randomised; Interventional; Design type: Treatment, Education or Self-Management, Complex Intervention

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Specialty: Stroke, Primary sub-specialty: Rehabilitation; UKCRC code/ Disease: Stroke/ Cerebrovascular diseases

Intervention

Participating sites will be randomised on a 1:1 basis to one of two study arms

Control arm: Participants receive standard care as provided by their treating clinician.

Intervention arm: Participants receive an initial face-to-face meeting with a trained facilitator approximately six months after stroke that seeks to help stroke survivors identify any unmet needs they may have and then work with them to address these needs. A priming tool/phamplet, which also details the date and time of the meeting, is sent out in advance. This tool highlights some of the issues which may be covered, and prompts the survivor to note down which, if any, may be relevant to them. At the meeting, these issues and needs are discussed and a supported self-management approach is introduced with the aim of addressing needs through individualised problem-solving. The process involves facilitated action-planning, goal-setting, and review, all of which are supported by a flexible document – the Moving Forward Guide. The intervention directly identifies and addresses unmet needs, and seeks to enhance participation by providing usable information and assisting the participant to build and sustain a flexible support network. Stroke survivors can have as many meetings with the facilitators as required, it is anticipated that most stroke survivors will have at least three visits and support may also be provided via the internet, phone or email.

Trial participants will be followed up using postal questionnaires at 3, 6 and 9 months.

Intervention type

Other

Phase

Drug names

Primary outcome measures

1. Acceptability of recruitment methods for sites is determined using site feasibility questionnaires and face to face/telephone discussions with site teams collected prior to trial opening
2. Acceptability of recruitment methods for participants is measured using screening data and face to face/telephone discussions with site teams throughout the recruitment period
3. Acceptability of implementation and delivery of the intervention is measured by collecting training records, collecting data on competency assessment, treatment records and data collected as part of a detailed process evaluation throughout the training recruitment and follow up period
4. Acceptability of collecting questionnaires at baseline, 3, 6 and 9 months is determined through number of patients who completed the questionnaires at baseline, 3, 6 and 9 months
5. Routinely offered services (usual care) is defined through feasibility questionnaires and face to face/telephone discussions with site teams, collected throughout the trial
6. Safety is measured by collecting adverse events continuously throughout the trial
7. Health economics analysis is conducted using the health economics resource use questionnaire, the EQ5D and the ICECAP-A at baseline, 3, 6 and 9 months

Secondary outcome measures

No secondary outcome measures

Overall trial start date

01/02/2015

Overall trial end date

30/09/2018

Reason abandoned

Eligibility

Participant inclusion criteria

Stroke Service Inclusion Criteria:
1. Encompasses primary and secondary care over a defined geographical area within the United Kingdom (UK)
2. Includes a stroke unit which fulfils the RCP guidelines definition of a stroke unit
3. Agree to try and establish a robust mechanism to identify all stroke survivors at four to seven months post stroke
4. Have the facilities and capacity to deliver the Moving Forward intervention
5. Fully supportive of time required for Moving Forward training, including two face to face away days and online training
6. Agreement to be involved via signed model Non-Commercial Agreement (mNCA) and local management approval

Stroke survivor inclusion criteria:
1. At least four months and not more than seven months since confirmed primary diagnosis of new stroke
2. Are residing in the community (i.e. not in a nursing or residential care home
3. Provide written informed consent or consultee assent

Carer inclusion criteria (participation optional):
1. Identified by the stroke survivor, as the main informal caregiver who provides the stroke survivor with support a minimum of once per week
2. Provided informed consent (i.e. implied via return of completed baseline questionnaire)

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned Sample Size: 200; UK Sample Size: 200

Participant exclusion criteria

Stroke services exclusion criteria:
1. Previously participated in the development of the intervention; as part of this programme of research or are intending to implement the Moving Forward intervention within the proposed duration of the study will not be eligible because these sites might be expected to have enhanced skills or knowledge about the Moving Forward intervention
2. Stroke services that are currently delivering or planning to deliver a similar supported self-management intervention

Stroke survivors exclusion criteria:
1. Main requirement is palliative care
2. Have concurrent major illness which is likely to predominately determine care (e.g. in receipt of consistent medical input from a specialist other than stroke/neurologist)
3. Stroke survivors not resident within the geographical area covered by the stroke service

Carer exclusion criteria:
Their stroke survivor does not consent for carer involvement.

Recruitment start date

15/09/2016

Recruitment end date

15/05/2017

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Edgware Community Hospital
Burnt Oak Broadway
Edgware
HA8 0AD
United Kingdom

Trial participating centre

St George's Hospital
Blackshaw Road
Tooting
SW17 0QT
United Kingdom

Trial participating centre

Singleton Hospital
Sketty Lane Sketty
Swansea
SA2 8QA
United Kingdom

Trial participating centre

Morriston Hospitals
Heol Maes Eglwys Morriston
Swansea
SA6 6NL
United Kingdom

Trial participating centre

Norwich Community Hospital
Bowthorpe Road
Norwich
NR2 3TU
United Kingdom

Trial participating centre

Sandwell General Hospital
Lyndon
West Bromwich
B71 4HJ
United Kingdom

Trial participating centre

Gloucestershire Royal Hospital
Great Western Road
Gloucester
GL1 3NN
United Kingdom

Sponsor information

Organisation

Bradford Teaching Hospitals NHS Foundation Trust

Sponsor details

Research Management & Support Office
Bradford Institute for Health Research
Bradford Royal Infirmary
Duckworth Lane
Bradford
BD9 6RJ
United Kingdom

Sponsor type

Hospital/treatment centre

Website

Funders

Funder type

Government

Funder name

National Institute for Health Research

Alternative name(s)

NIHR

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

1. Presentation of results at the UK Stroke Forum, at the Yorkshire Consumer Conference and at the annual conference of the Association of Directors of Social Services (ADSS)
2. All research participants will be made aware that results will be posted on the Programme website

Intention to publish date

30/09/2019

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

29/06/2016: Internal review.